

<b>Lab No.</b> : SG2/15-01-2024/SR8634294	<b>Lab Add.</b> : Sevoke Road, Siliguri 734001
<b>Patient Name</b> : AMRIT SINGH	<b>Ref Dr.</b> : Dr.MEDICAL OFFICER
<b>Age</b> : 34 Y 0 M 0 D	<b>Collection Date</b> : 15/Jan/2024 09:00AM
<b>Gender</b> : M	<b>Report Date</b> : 15/Jan/2024 12:51PM



**DEPARTMENT OF BIOCHEMISTRY**

Test Name	Result	Bio Ref. Interval	Unit
<b>*BILIRUBIN (TOTAL) , GEL SERUM</b>			
BILIRUBIN (TOTAL) (Method:DIAZONIUM ION )	0.50	0.2 - 1.2	mg/dL
<b>SGPT/ALT , GEL SERUM</b>			
(Method:UV WITH P5P)	41	16 - 63	U/L
<b>SODIUM,BLOOD</b>			
(Method:ISE INDIRECT)	139	136 - 145	mEq/L
<b>POTASSIUM,BLOOD</b>			
(Method:ISE INDIRECT)	<u>5.20</u>	3.5 - 5.1	mEq/L
<b>UREA,BLOOD</b>			
(Method:UREASE-COLORIMETRIC )	21.0	12.8-42.8	mg/dl

CHECKED TWICE

<b>URIC ACID,BLOOD</b>	6.29	3.5 - 7.2	mg/dl
(Method:URICASE ,COLORIMETRIC )			
<b>*TOTAL PROTEIN [BLOOD] ALB:GLO RATIO , .</b>			
TOTAL PROTEIN (Method:BIURET METHOD)	7.74	6.6 - 8.7	g/dL
ALBUMIN (Method:BCP)	<u>0.4</u>	3.4 -5.0 g/dl	g/dl
GLOBULIN (Method:Calculated)	<u>7.33</u>	1.8-3.2	g/dl
AG Ratio (Method:Calculated)	<u>0.06</u>	1.0 - 2.5	
<b>CALCIUM,BLOOD</b>			
(Method:OCPC)	9.17	8.6-10.0 mg/dl	mg/L

CHECKED TWICE

<b>LIPID PROFILE , GEL SERUM</b>			
CHOLESTEROL-TOTAL (Method:CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE)	156	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	mg/dl
TRIGLYCERIDES (Method:ENZYMATIC, END POINT)	133	NORMAL < 150 BORDERLINE HIGH 150-199 HIGH 200-499 VERY HIGH > 500	mg/dl
HDL CHOLESTEROL (Method:DIRECT MEASURE-PEG )	<u>38</u>	NO RISK : >60 mg/dL, MODERATE RISK : 40-60 mg/dL, HIGH RISK : <40 mg/dL	mg/dl
LDL CHOLESTEROL DIRECT (Method:DIRECT MEASURE )	100	OPTIMAL : <100 mg/dL, Near optimal/ above optimal : 100-129 mg/dL, Borderline high : 130-159 mg/dL, High : 160-189 mg/dL, Very high : >=190 mg/dL	mg/dl
VLDL (Method:Calculated)	17	< 40 mg/dl	mg/dL
CHOL HDL Ratio (Method:Calculated)	4.0	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0	

<b>Lab No.</b> : SG2/15-01-2024/SR8634294	<b>Lab Add.</b> : Sevoke Road, Siliguri 734001
<b>Patient Name</b> : AMRIT SINGH	<b>Ref Dr.</b> : Dr. MEDICAL OFFICER
<b>Age</b> : 34 Y 0 M 0 D	<b>Collection Date</b> : 15/Jan/2024 09:00AM
<b>Gender</b> : M	<b>Report Date</b> : 15/Jan/2024 12:51PM



**DEPARTMENT OF BIOCHEMISTRY**

Test Name	Result	Bio Ref. Interval	Unit
		HIGH RISK >11.0	

<b>SGOT/AST</b> (Method:UV WITH P5P)	<b>73</b>	15 - 37	U/L
---	-----------	---------	-----

<b>GLUCOSE, FASTING</b> (Method:Hexokinase Method)	93	70 - 100	mg/dl
---	----	----------	-------

<b>BILIRUBIN (DIRECT)</b> (Method:DIAZOTIZATION)	<b>0.05</b>	< 0.2	mg/dL
---	-------------	-------	-------

<b>CREATININE, BLOOD</b> (Method: ALKALINE PICRATE)	0.86	0.70 - 1.30	mg/dl
--	------	-------------	-------

<b>*THYROID PANEL (T3, T4, TSH) , GEL SERUM</b>			
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.13	0.60 - 1.81 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	6.4	4.5 - 10.9	microgram/dl
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	3.16	0.35-5.5	µIU/mL

**BIOLOGICAL REFERENCE INTERVAL : [ONLY FOR PREGNANT MOTHERS]**

**Trimester specific TSH LEVELS during pregnancy:**

FIRST TRIMESTER : 0.10 - 2.50 µ IU/mL  
 SECOND TRIMESTER : 0.20 - 3.00 µ IU/mL  
 THIRD TRIMESTER : 0.30 - 3.00 µ IU/mL

**References :**

1. Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. *Clinical Practice Guidelines, New Delhi: Elsevier; 2012.*
2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. *Thyroid 2011; 21: 1081-25.*
3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. *Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: <http://www.ijem.in/text.asp?2014/18/5/735/139221>.*

<b>ALKALINE PHOSPHATASE</b> (Method:P-NPP,AMP BUFFER)	88	46 - 116	U/L
--	----	----------	-----

<b>CHLORIDE, BLOOD</b> (Method:ISE INDIRECT)	103	98 - 107	mEq/L
---	-----	----------	-------

<b>*GLYCATED HAEMOGLOBIN (HBA1C) , EDTA WHOLE BLOOD</b>			
GLYCATED HEMOGLOBIN (HBA1C)	4.5	***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***	%
HbA1c (IFCC) (Method:HPLC)	26.0		mmol/mol

**Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:**

**Lab No.** : SG2/15-01-2024/SR8634294

<b>Lab No.</b> : SG2/15-01-2024/SR8634294	<b>Lab Add.</b> : Sevoke Road, Siliguri 734001
<b>Patient Name</b> : AMRIT SINGH	<b>Ref Dr.</b> : Dr.MEDICAL OFFICER
<b>Age</b> : 34 Y 0 M 0 D	<b>Collection Date</b> : 15/Jan/2024 09:00AM
<b>Gender</b> : M	<b>Report Date</b> : 15/Jan/2024 12:51PM



**DEPARTMENT OF BIOCHEMISTRY**

Test Name	Result	Bio Ref. Interval	Unit
Low risk / Normal / non-diabetic	<5.7% (NGSP)	/ < 39 mmol/mol (IFCC)	
Pre-diabetes/High risk of Diabetes	5.7%- 6.4% (NGSP)	/ 39 - < 48 mmol/mol (IFCC)	
Diabetics-HbA1c level	>= 6.5% (NGSP)	/ > 48 mmol/mol (IFCC)	

**Analyzer used : Bio-Rad D 10**  
**Method : HPLC Cation Exchange**

**Recommendations for glycemic targets**

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
  - Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
  - Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
  - Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
  - Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
  - Ø Some patients may benefit from HbA1c goals that are stringent.
- Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.
- Reference: Glycated hemoglobin monitoring BMJ 2006; 333:586-8

**References:**

1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

[PDF Attached](#)

<b>PHOSPHORUS-INORGANIC,BLOOD</b>	3.0	2.5-4.5 mg/dl	mg/dl
<small>(Method:UV PHOSPHOMOLYBDATE)</small>			

\*\*\* End Of Report \*\*\*

**DR. SANJAY KR. AGARWALA**  
MD CONSULTANT BIOCHEMIST



<b>Lab No.</b>	: SG2/15-01-2024/SR8634294	<b>Lab Add.</b>	: Newtown,Kolkata-700156
<b>Patient Name</b>	: AMRIT SINGH	<b>Ref Dr.</b>	: Dr.MEDICAL OFFICER
<b>Age</b>	: 34 Y 0 M 0 D	<b>Collection Date</b>	: 15/Jan/2024 09:29AM
<b>Gender</b>	: M	<b>Report Date</b>	: 16/Jan/2024 03:33PM



**DEPARTMENT OF BIOCHEMISTRY**

Test Name	Result	Bio Ref. Interval	Unit
<b>URIC ACID, URINE, SPOT URINE</b>			
URIC ACID, SPOT URINE (Method:URICASE) ESTIMATED TWICE	<b>9.00</b>	37-92 mg/dL	mg/dL

\*\*\* End Of Report \*\*\*

**DR. ANANNYA GHOSH**  
MBBS, MD (Biochemistry)  
Consultant Biochemist



MC-2176

<b>Lab No.</b> : SG2/15-01-2024/SR8634294	<b>Lab Add.</b> : Sevoke Road, Siliguri 734001
<b>Patient Name</b> : AMRIT SINGH	<b>Ref Dr.</b> : Dr. MEDICAL OFFICER
<b>Age</b> : 34 Y 0 M 0 D	<b>Collection Date</b> : 15/Jan/2024 08:59AM
<b>Gender</b> : M	<b>Report Date</b> : 15/Jan/2024 06:29PM

**DEPARTMENT OF HAEMATOLOGY**

Test Name	Result	Bio Ref. Interval	Unit
<b>*CBC WITH PLATELET (THROMBOCYTE) COUNT , EDTA WHOLE BLOOD</b>			
HEMOGLOBIN (Method:SLS haemoglobin method)	15.5	13 - 17	g/dL
WBC (Method:DC detection method)	6.5	4 - 10	*10 <sup>3</sup> /μL
RBC (Method:DC detection method)	4.93	4.5 - 5.5	*10 <sup>6</sup> /μL
PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy)	208	150 - 450*10 <sup>3</sup>	*10 <sup>3</sup> /μL
<b><u>DIFFERENTIAL COUNT</u></b>			
NEUTROPHILS (Method:Flowcytometry/Microscopy)	56	40 - 80 %	%
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	39	20 - 40 %	%
MONOCYTES (Method:Flowcytometry/Microscopy)	02	2 - 10 %	%
EOSINOPHILS (Method:Flowcytometry/Microscopy)	03	1 - 6 %	%
BASOPHILS (Method:Flowcytometry/Microscopy)	00	0-0.9%	%
<b><u>CBC SUBGROUP</u></b>			
HEMATOCRIT / PCV (Method:Calculated)	46.9	40 - 50 %	%
MCV (Method:Calculated)	95.1	83 - 101 fl	fl
MCH (Method:Calculated)	31.5	27 - 32 pg	pg
MCHC (Method:Calculated)	33.1	31.5-34.5 gm/dl	gm/dl
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	12.7	11.6-14%	%
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	38.0	8.3 - 25 fL	fL
MPV-MEAN PLATELET VOLUME (Method:Calculated)	14.1	7.5 - 11.5 fl	
RBC	NORMOCYTIC NORMOCHROMIC.		
WBC.	NORMAL MORPHOLOGY		
PLATELET	ADEQUATE ON SMEAR.		

<b>ESR (ERYTHROCYTE SEDIMENTATION RATE) , EDTA WHOLE BLOOD</b>			
1stHour (Method:Westergren)	06	0.00 - 20.00 mm/hr	mm/hr

<b>BLOOD GROUP ABO+RH [GEL METHOD] , EDTA WHOLE BLOOD</b>	
ABO (Method:Gel Card)	B
RH (Method:Gel Card)	POSITIVE

**Gel technology Dia Med ID Micro typing system is the latest technology in transfusion Medicine. It gives more reproducible and standardized test results.**

Lab No. : SG2/15-01-2024/SR8634294

Page 5 of 12



MC-2176

<b>Lab No.</b>	: SG2/15-01-2024/SR8634294	<b>Lab Add.</b>	: Sevoke Road, Siliguri 734001
<b>Patient Name</b>	: AMRIT SINGH	<b>Ref Dr.</b>	: Dr.MEDICAL OFFICER
<b>Age</b>	: 34 Y 0 M 0 D	<b>Collection Date</b>	: 15/Jan/2024 08:59AM
<b>Gender</b>	: M	<b>Report Date</b>	: 15/Jan/2024 06:29PM



### DEPARTMENT OF HAEMATOLOGY

Test Name	Result	Bio Ref. Interval	Unit
-----------	--------	-------------------	------

It more repaid, reliable, very sensitive and objective , and hence more consistent and comparable results are obtained.  
 Single used cards are individualised for every patient and results can be photographed / scanned and stored for future use.  
 Special instruments that are used only for this technology also reduce risk of any contamination.

Ref:- WHO technical manual on transfusion medicine-Second Edition 2003

**(RESULTS ALSO VERIFIED BY : FORWARD AND REVERSE GROUPING (TUBE AND SLIDE METHOD))**

**TECHNOLOGY USED: GEL METHOD**

#### ADVANTAGES :

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty  
 MBBS, MD (Path), IFCAP  
 Reg. No. 65992 (WBMC)

Lab No.	: SG2/15-01-2024/SR8634294	Lab Add.	:
Patient Name	: AMRIT SINGH	Ref Dr.	: Dr.MEDICAL OFFICER
Age	: 34 Y 0 M 0 D	Collection Date	:
Gender	: M	Report Date	: 15/Jan/2024 11:32AM



**DEPARTMENT OF RADIOLOGY**  
**X-RAY REPORT OF CHEST (PA)**

**FINDINGS:**

- Cardiac size appears within normal limits. Margin is well visualised and cardiac silhouette is smoothly outlined. Shape is within normal limit.
- Lung parenchyma shows no focal lesion. No general alteration of radiographic density. Apices are clear. Bronchovascular lung markings are within normal.
- Lateral costo-phrenic angles are clear.
- Domes of diaphragm are smoothly outlined. Position is within normal limits.

**IMPRESSION :**

**Normal study.**

\*\*\* End Of Report \*\*\*

  
**DR. MUKTI SARKAR MD.**  
**CONSULTANT RADIOLOGIST**



MC-2176

<b>Lab No.</b> : SG2/15-01-2024/SR8634294	<b>Lab Add.</b> : Sevoke Road, Siliguri 734001
<b>Patient Name</b> : AMRIT SINGH	<b>Ref Dr.</b> : Dr. MEDICAL OFFICER
<b>Age</b> : 34 Y 0 M 0 D	<b>Collection Date</b> : 15/Jan/2024 09:28AM
<b>Gender</b> : M	<b>Report Date</b> : 15/Jan/2024 02:58PM

**DEPARTMENT OF CLINICAL PATHOLOGY**

Test Name	Result	Bio Ref. Interval	Unit
<b>URINE ROUTINE ALL, ALL , URINE</b>			
<b><u>PHYSICAL EXAMINATION</u></b>			
COLOUR	PALE YELLOW		
APPEARANCE	SLIGHTLY HAZY		
<b><u>CHEMICAL EXAMINATION</u></b>			
pH (Method:Dipstick (triple indicator method))	6.0	4.6 - 8.0	
SPECIFIC GRAVITY (Method:Dipstick (ion concentration method))	1.025	1.005 - 1.030	
PROTEIN (Method:Dipstick (protein error of pH indicators)/Manual)	ABSENT	NOT DETECTED	
GLUCOSE (Method:Dipstick(glucose-oxidase-peroxidase method)/Manual)	ABSENT	NOT DETECTED	
KETONES (ACETOACETIC ACID, ACETONE) (Method:Dipstick (Legals test)/Manual)	ABSENT	NOT DETECTED	
BLOOD (Method:Dipstick (pseudoperoxidase reaction))	NEGATIVE	NOT DETECTED	
BILIRUBIN (Method:Dipstick (azo-diazo reaction)/Manual)	NEGATIVE	NEGATIVE	
UROBILINOGEN (Method:Dipstick (diazonium ion reaction)/Manual)	NEGATIVE	NEGATIVE	
NITRITE (Method:Dipstick (Griess test))	NEGATIVE	NEGATIVE	
LEUCOCYTE ESTERASE (Method:Dipstick (ester hydrolysis reaction))	NEGATIVE	NEGATIVE	
<b><u>MICROSCOPIC EXAMINATION</u></b>			
LEUKOCYTES (PUS CELLS) (Method:Microscopy)	0-1	0-5	/hpf
EPITHELIAL CELLS (Method:Microscopy)	0-1	0-5	/hpf
RED BLOOD CELLS (Method:Microscopy)	ABSENT	0-2	/hpf
CAST (Method:Microscopy)	ABSENT	NOT DETECTED	
CRYSTALS (Method:Microscopy)	ABSENT	NOT DETECTED	
BACTERIA (Method:Microscopy)	FEW	NOT DETECTED	
YEAST (Method:Microscopy)	ABSENT	NOT DETECTED	
OTHERS	ABSENT		

**Note:**

- All urine samples are checked for adequacy and suitability before examination.
- Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- Negative nitrite test does not exclude urinary tract infections.
- Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can

Lab No. : SG2/15-01-2024/SR8634294

Page 8 of 12





MC-2176

<b>Lab No.</b> : SG2/15-01-2024/SR8634294	<b>Lab Add.</b> : Sevoke Road, Siliguri 734001
<b>Patient Name</b> : AMRIT SINGH	<b>Ref Dr.</b> : Dr.MEDICAL OFFICER
<b>Age</b> : 34 Y 0 M 0 D	<b>Collection Date</b> : 15/Jan/2024 09:28AM
<b>Gender</b> : M	<b>Report Date</b> : 15/Jan/2024 02:58PM



### DEPARTMENT OF CLINICAL PATHOLOGY

Test Name	Result	Bio Ref. Interval	Unit
-----------	--------	-------------------	------

occur due to cell lysis.

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty  
MBBS, MD (Path), IFCAP  
Reg. No. 65992 (WBMC)



Lab No.	: SG2/15-01-2024/SR8634294	Lab Add.	:
Patient Name	: AMRIT SINGH	Ref Dr.	: Dr.MEDICAL OFFICER
Age	: 34 Y 0 M 0 D	Collection Date	:
Gender	: M	Report Date	: 15/Jan/2024 12:11PM

**DEPARTMENT OF CARDIOLOGY**  
**REPORT OF E.C.G.**

HEART RATE : 62 /min.  
RHYTHM : Regular sinus.  
P-WAVE : Normal  
P - R INTERVAL : 160 ms,  
QRS DURATION : 80 ms  
QRS CONFIGURATION : NORMAL  
QRS VOLTAGE : R/S in V1 2/8 mm.  
R/S in V6 8/1 mm.  
QRS AXIS : +30°  
Q- Waves : No significant Q-wave.  
QT TIME : Normal.  
ST SEGMENT : Normal.  
T WAVE : NORMAL  
ROTATION : Normal.  
OTHER FINDINGS : Nil.  
**IMPRESSION : ECG WITHIN NORMAL LIMIT.**

\*\*\* End Of Report \*\*\*

  
Dr. ARABINDA SAHA (MD,DM)  
CONSULTANT CARDIOLOGIST

Lab No. : SG2/15-01-2024/SR8634294  
Patient Name : AMRIT SINGH  
Age : 34 Y O M O D  
Gender : M

Lab Add. :  
Ref Dr. : Dr.MEDICAL OFFICER  
Collection Date :  
Report Date : 15/Jan/2024 11:35AM



**DEPARTMENT OF ULTRASONOGRAPHY**  
**REPORT ON EXAMINATION OF WHOLE ABDOMEN**

**LIVER**

Liver is normal in size having normal shape, regular smooth outline and of homogeneous echotexture. **Segment VI shows simple cyst measuring 7 x 6 mm.** Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal.

**PORTA**

The appearance of porta is normal. Common Bile duct is normal with no intraluminal pathology (Calculi /mass) could be detected at its visualised part. Portal vein is normal at porta.

**GALL BLADDER**

Gallbladder is physiologically distended. Wall thickness appears normal. No intraluminal pathology (Calculi/mass) could be detected. Sonographic Murphys sign is negative.

**PANCREAS**

Echogenecity appears within limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

**SPLEEN**

Spleen is normal in size (112 mm). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

**KIDNEYS**

Both kidneys are normal in shape, size (Rt. kidney 99 mm. & Lt. kidney 103 mm) axes & position. Cortical echogenecity appears normal maintaining corticomedullary differentiation. Margin is regular and cortical thickness is uniform. No calcular disease noted. No hydronephrotic changes detected.

**URETERS**

Visualised part of upper ureters are not dilated.

**URINARY BLADDER**

Urinary bladder is distended, wall thickness appeared normal. No intraluminal pathology (calculi / mass) could be detected.

**PROSTATE**

Prostate is normal in size. Echotexture appears within normal limits. No focal alteration of its echogenecity could be detected.

It measures : 37 x 33 x 33 mm.

Approximate weight could be around = 22 gms.

**IMPRESSION**

**Simple hepatic cyst.**

**Please correlate clinically.**

Lab No. : SG2/15-01-2024/SR8634294

Lab Add. :

Patient Name : AMRIT SINGH

Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 0 M 0 D

Collection Date :

Gender : M

Report Date : 15/Jan/2024 11:35AM



**Kindly note**

➤ Ultrasound is not the modality of choice to rule out subtle bowel lesion.

➤ Please Intimate us for any typing mistakes and send the report for correction within 7 days.

➤ The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.


**The report and films are not valid for medico-legal purpose.**

Patient Identity not verified.

**DR. Ziaul Mustafa**  
MD, Radiodiagnosis

**Patient report**

Sample ID: D02135455974  
 Injection date 15/01/2024 03:18 PM  
 Injection #: 8 D-10 Method: HbA1c  
 Rack #: --- Rack position: 2  
 Bio-Rad v: 5.00-2 S/N: #DM23F10804



Peak table - ID: D02135455974

Peak	R.time	Height	Area	Area %
A1a	0.22	4419	18684	0.6
A1b	0.30	8584	36231	1.2
F	0.53	1149	5701	0.2
LA1c/CHb-1	0.68	5978	47464	1.6
A1c	0.89	10580	87812	4.5
P3	1.36	38038	139923	4.7
A0	1.42	1064422	2662553	88.8
Total Area:		2998368		

Concentration:	%	mmol/mol
A1c	4.5	26